Examining High-Potency API Manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Examining High-Potency API Manufacturing
High-potency manufacturing of active pharmaceutical ingredients is a growing and specialized capability.


Pharmaceutical Technology
Volume 33, Issue 7, pp. 42-46

A case study

Understanding the requirements for HPAPI manufacturing and related costs is critical for a CMO or pharmaceutical company interested in expanding or adding HPAPI capacity. The CMO SAFC (St. Louis, MO) went through this decision-making process in several recent expansions. The company has invested $75 million during the past 18 months to expand its HPAPI capacity. These investments include: a $4.5-million project to add a CGMP pilot plant and kilo-laboratory capacity at its Madison, Wisconsin, facility, completed in early 2008; a $29-million investment to expand bacterial and fungal fermentation-derived HPAPI capacity at its site in Jerusalem, Israel, due for completion in early 2010; and a $30-million investment to build a new commercial-scale HPAPI facility at Madison, due to be completed by year-end 2009. SAFC also commissioned a conjugation suite for HPAPIs in September 2008. It invested $12 million for expanding its viral manufacturing capacity (Biosafety Level 2-compliant at its facility in Carlsbad, California. This expansion is to become operational in the second half of 2009.


Growth in oncology drugs
Small-molecule HPAPI manufacturing . SAFC is building a new commercial-scale HPAPI plant in Madison following several expansions at its facility there. "We made the decision to expand our services by building from scratch rather than acquiring another building or CMO since there would have inevitably have been a great deal of retrofitting necessary," says Dave Backer, director of business development and marketing at SAFC Pharma. "When it comes to HPAPI facility design, SAFC has always felt that it is better to build a facility with the type of products to be manufactured in that facility rather than to try and build into existing facilities, which may not have the containment principles in place already."

SAFC made two previous expansions at its Madison HPAPI facility, but needed additional capacity for large-scale and commercial capabilities. Construction began in the fall of 2008 and will be completed by the end of 2009. The new facility will be capable of manufacturing, handling, and transferring large volumes of product up to 4000 L. This capacity will allow for batches of potent compounds to be manufactured in the range of hundreds of kilograms. The material-handling systems are being designed for full containment on a large scale. The company is adding a milling and micronization area in the facility for potent compounds. The facility is designed to adhere to Category IV standards, as defined by SafeBridge Consultants. SAFC's existing facility in Madison is certified by SafeBridge, and the company intends to seek certification for the new facility upon its completion. "Safety and consistency are paramount, and it is important to note that in addition to very careful facility design that SAFC has work processes and very experienced staff," which the company uses in its small- and large-scale HPAPI manufacturing, adds Backer.

Antibody–drug conjugates . SAFC recently received SafeBridge certification for its high-potency antibody–drug conjugation suite in St. Louis to complement such certification for its high-potency manufacturing facilities in Madison. "For the high-potency conjugation suite in St. Louis, we wanted to take the best practices that we had in facility design, operator training, and operator safety that has been in operation for years at our Madison plant, and marry it to the conjugation and biologics capabilities and expertise already employed at our St. Louis facility," continues Backer.

SAFC's high-potent conjugation facility was designed from its inception as a containment facility. Some key factors in designing such a facility are room-pressure differentials, with appropriate monitoring and verification, to ensure that the pressure of the major handling area is negative to its surrounding airlocks and vestibules. Single-pass air is used with temperature, humidity, and particulate controls. Misting showers are part of the degowning and exit process for operators and equipment. The suite also has filtration and capture equipment, both with the isolators and with the exhaust system of the heating, ventilation, and air-conditioning system. Isolators and fume hoods are used for certain operations as are biologic safety cabinets. Other facility designs such as unidirectional flow and restricted access are consistent with most recently built biologics facilities."

"Traditional biologics facilities that produce proteins and antibodies in mammalian-cell-culture or bacterial fermentation are designed to have the suites where purification occurs be positive to their surroundings. However, when working with potent products, such as viruses or biologics that are conjugated to highly potent APIs, processes are performed in a suite negative to the surrounding rooms to ensure the potent compounds are contained within the working environment," explains Backer. "Protection of the operators is also an absolute requirement. The operators are well trained in operating with protective garments and wear respirators," he adds. "Training in the handling of high-potent products is ongoing and essential. Changeover processes are validated and in place."

SAFC employs this negative-room-pressure concept at its facilities for viral-vaccine manufacturing in Carlsbad, its small-molecule HPAPI manufacturing facility in Madison, and its potent antibody–drug conjugation suite in St. Louis. The company is also including this approach at its fermentation facility in Jerusalem, which will target potent and cytotoxic molecules, and at the company's new large-scale, small-molecule HPAPI commercial manufacturing facility in Wisconsin.

As with all HPAPI facilities, operator safety is key. "Demonstrating that controls are in place to ensure the highest levels of safety to workers and the environment is an important consideration," says Backer. "The operators are well trained in operating with protective garments and wear respirators. Training in the handling of high-potent products is ongoing and essential. Changeover processes are validated and in place." He adds that SafeBridge certification adds assurance that there will not be interruptions in manufacture due to safety concerns.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here